139 related articles for article (PubMed ID: 25430486)
21. [Allogeneic hematopoietic stem cell transplantation following reduced intensity conditioning regimen for treatment of refractory leukemia].
Jiang JL; Yan SK; Yang J; Cai Y; Wan LP; Qin YW; Wang C
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):517-21. PubMed ID: 19112913
[TBL] [Abstract][Full Text] [Related]
22. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.
Ringdén O; Labopin M; Ehninger G; Niederwieser D; Olsson R; Basara N; Finke J; Schwerdtfeger R; Eder M; Bunjes D; Gorin NC; Mohty M; Rocha V
J Clin Oncol; 2009 Sep; 27(27):4570-7. PubMed ID: 19652066
[TBL] [Abstract][Full Text] [Related]
23. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
24. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.
Hussein AA; Al-Zaben A; Ghatasheh L; Natsheh A; Hammada T; Abdel-Rahman F; Abu-Jazar H; Sharma S; Najjar R; Frangoul H
Pediatr Blood Cancer; 2013 Aug; 60(8):1345-9. PubMed ID: 23424175
[TBL] [Abstract][Full Text] [Related]
25. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
[TBL] [Abstract][Full Text] [Related]
26. Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
Tanaka J; Kanamori H; Nishiwaki S; Ohashi K; Taniguchi S; Eto T; Nakamae H; Minagawa K; Miyamura K; Sakamaki H; Morishima Y; Kato K; Suzuki R; Nishimoto N; Oba K; Masauzi N
Bone Marrow Transplant; 2013 Nov; 48(11):1389-94. PubMed ID: 23665820
[TBL] [Abstract][Full Text] [Related]
27. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients.
Topcuoglu P; Arat M; Ozcan M; Arslan O; Ilhan O; Beksac M; Gurman G
Ann Hematol; 2012 Apr; 91(4):577-86. PubMed ID: 21971669
[TBL] [Abstract][Full Text] [Related]
28. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
[TBL] [Abstract][Full Text] [Related]
29. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
Bennett C; Waters T; Stinson T; Almagor O; Pavletic Z; Tarantolo S; Bishop M
Bone Marrow Transplant; 1999 Sep; 24(5):555-60. PubMed ID: 10482942
[TBL] [Abstract][Full Text] [Related]
30. Non-TBI hematopoietic stem cell transplantation in pediatric AML patients: a single-center experience.
Hamidieh AA; Alimoghaddam K; Jahani M; Bahar B; Mousavi SA; Iravani M; Behfar M; Jalali A; Jalili M; Hamdi A; Ghavamzadeh A
J Pediatr Hematol Oncol; 2013 Aug; 35(6):e239-45. PubMed ID: 23042019
[TBL] [Abstract][Full Text] [Related]
31. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of total body irradiation, cyclophosphamide, and cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Mori T; Aisa Y; Kato J; Yamane A; Nakazato T; Shigematsu N; Okamoto S
Am J Hematol; 2012 Apr; 87(4):349-53. PubMed ID: 22290459
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Lee JH; Joo YD; Kim H; Ryoo HM; Kim MK; Lee GW; Lee JH; Lee WS; Park JH; Bae SH; Hyun MS; Kim DY; Kim SD; Min YJ; Lee KH
J Clin Oncol; 2013 Feb; 31(6):701-9. PubMed ID: 23129746
[TBL] [Abstract][Full Text] [Related]
34. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of allogeneic haemopoietic stem cell transplants at a small New Zealand centre: does size matter?
Ganly P; Cole S; Trengrove A; Butler A
Intern Med J; 2014 Jul; 44(7):683-9. PubMed ID: 24750295
[TBL] [Abstract][Full Text] [Related]
36. [A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
Nakamae H; Terada Y; Nakane T; Koh H; Nakamae M; Aimoto R; Hirose A; Hayashi Y; Nishimoto M; Inoue E; Yoshimura T; Inoue A; Koh KR; Yamane T; Hino M
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1691-5. PubMed ID: 20841930
[TBL] [Abstract][Full Text] [Related]
37. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.
Lissandre S; Bay JO; Cahn JY; Porcher R; Cacheux V; Cabrespine A; Cornillon J; Cassinat B; Peffault de Latour R; Socie G; Robin M
Bone Marrow Transplant; 2011 Apr; 46(4):557-61. PubMed ID: 21042309
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up.
Shimoni A; Hardan I; Shem-Tov N; Yerushalmi R; Nagler A
Leukemia; 2010 May; 24(5):1050-2. PubMed ID: 20147978
[No Abstract] [Full Text] [Related]
39. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
Yanada M; Naoe T; Iida H; Sakamaki H; Sakura T; Kanamori H; Kodera Y; Okamoto S; Kanda Y; Sao H; Asai O; Nakai K; Maruta A; Kishi K; Furukawa T; Atsuta Y; Yamamoto K; Tanaka J; Takahashi S
Bone Marrow Transplant; 2005 Nov; 36(10):867-72. PubMed ID: 16113659
[TBL] [Abstract][Full Text] [Related]
40. Umbilical cord blood as an alternative source of reduced-intensity hematopoietic stem cell transplantation for chronic Epstein-Barr virus-associated T or natural killer cell lymphoproliferative diseases.
Sawada A; Inoue M; Koyama-Sato M; Kondo O; Yamada K; Shimizu M; Isaka K; Kimoto T; Kikuchi H; Tokimasa S; Yasui M; Kawa K
Biol Blood Marrow Transplant; 2014 Feb; 20(2):214-21. PubMed ID: 24188918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]